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LONG-TERM OUTCOMES OF SWITCHING PATIENTS WITH TYPE 2 
DIABETES FROM BIPHASIC INSULIN TO BIPHASIC INSULIN ASPART 
30/70: AN IMPROVE STUDY SUBGROUP ANALYSIS
Ligthelm R1, Christensen TE2, Thomsen TL2, Yang W3
1EHM, Hoofddorp, The Netherlands, 2Novo Nordisk A/S, Virum, Denmark, 3China-Japan 
Friendship Hospital, Beijing, Beijing, China
OBJECTIVES: The IMPROVE study includes results of 52,419 patient’s after 26 
weeks of treatment with biphasic insulin aspart 30/70 (BIAsp30) in routine care 
setting. The aim of this analysis was to project long-term clinical outcomes in patients 
with type 2 diabetes from the IMPROVE study switched from biphasic human insulin 
(BHI) to BIAsp30. METHODS: In total, 4,368 patients on BHI from the IMPROVE 
study were used in the present analysis. The CORE Diabetes Model was used to 
project long-term clinical outcomes based on the baseline characteristics (male 58.2%, 
mean age 57.0 years, duration of diabetes 10.7 years, HbA1c 9.2%, BMI 26.2 kg/m2 
and total daily insulin dose 32.8 IU). Patients were assumed to either continue on BHI, 
or switch to BIAsp30 and obtain the signiﬁcant (p a 0.01) treatment effects of BIAsp30 
observed in the IMPROVE study (HbA1c improvement of 1.9 percentage points, 
0.24 kg weight loss and 29.3 less major hypoglycemic events per 100 patient years). 
RESULTS: The improved glycemic control resulting from a switch from BHI to 
BIAsp30 led to a projected delay in the onset of any diabetes-related complications of 
0.7 years (2.0 versus 1.3, respectively). E.g. the projected delay of suffering a myocar-
dial infarction was 1.7 for BIAsp30 and 1.4 years BHI. The cumulative incidence of 
complications was projected to decrease with BIAsp30 in the majority of parameters 
studied, e.g. the cumulative incidence of severe vision loss was projected to decrease 
by 8.5% (1.3 %-point absolute risk reduction) and strokes by 8.6% (1.1 %-point 
absolute risk reduction). The average life expectancy was projected to increase by 1.5 
years. CONCLUSIONS: The long-term health outcome projections based on end-
points reported in the IMPROVE study indicate that switching patients with type 2 
diabetes from BHI to BIAsp30 will improve life expectancy, delay the onset of diabe-
tes-related complications, and reduce their cumulative incidence over patient 
lifetimes.
PDB5
SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF 
VILDAGLIPTIN FOR TYPE 2 DIABETES MELLITUS
Walczak J, Nogas G, Organa M, Przada P, Potoczny R
Arcana Institute, Cracow, Poland
OBJECTIVES: The aim of the review was to compare the efﬁcacy and safety of 
vildagliptin versus glimepiride as add-on therapy to metformin in patients with type 
2 diabetes mellitus. METHODS: The analysis was performed in accordance with the 
rules of systematic review, based on the Cochrane Collaboration (Cochrane Review-
er’s Handbook) guidelines and the Health Technology Assessment Agency in Poland 
recommendations. Literature search strategy was performed within the main medical 
databases: Medline, Cochrane Library, EMBASE, Biomed Central and CRD. 
RESULTS: one study of high quality was identiﬁed according to predeﬁned selection 
criteria. The trial evaluated ﬁfty-two-week effectiveness of vildagliptin plus metformin 
versus glimepiride plus metformin. The analysis disclosed non inferior efﬁcacy of 
intervention and comparator in HbA1c reduction. The change in fasting plasma 
glucose was also comparable between groups. Patients in vildagliptin group more fre-
quently reached a target HbA1c level of 7% without hypoglycaemia (50.9% of par-
ticipants) than patients in glimepiride group (44.3% of participants). Furthermore 
vildagliptin was more efﬁcient in body weight reduction; WMD  1.79 (95% CI: 
2.11; 1.47). The risk of hypoglycaemia episodes was higher within glimepiride 
therapy; RR  0.10 (95% CI: 0.07; 0.16). Vildagliptin treatment resulted in lower 
incidence of adverse events, serious adverse events and discontinuation because of 
adverse events (respectively 74.5%, 7.1%, and 4.8% in vildagliptin group versus 
81.1%, 9.5%, and 7.7% in glimepiride group). The risk of cardiovascular complica-
tions was higher in comparative group but it was not statistically signiﬁcant. Dizziness, 
fatigue, asthenia, tremor, hyperhidrosis and hunger were signiﬁcantly less frequent in 
vildagliptin group. CONCLUSIONS: Vildagliptin as add-on therapy to metformin is 
more efﬁcient and safer technology than glimepiride combined with metformin in the 
treatment of type 2 diabetes mellitus.
PDB6
ADMINISTRATIVE CLAIMS ANALYSIS OF AN L-METHYLFOLATE 
COMBINATION PRODUCT IN PATIENTS WITH DIABETIC PERIPHERAL 
NEUROPATHY
Wade R1, Cai Q1, Thethi T2
1HealthCore, Inc, Wilmington, DE, USA, 2Tulane University Health Sciences Center, New 
Orleans, LA, USA
Oral administration of the combination prescription product containing L-methylfo-
late, pyridoxal-5’-phosphate, and methylcobalamin (MPM) has shown to increase 
epidermal nerve ﬁber density in humans, reduce neuropathic pain and restore sensa-
tion in patients with diabetic neuropathy (DPN). It is believed to increase vascular 
perfusion through lowering homocysteine and increasing nitric oxide levels. OBJEC-
TIVES: Evaluate the clinical and economic impact of orally-administered MPM on 
patients with diabetic peripheral neuropathy (DPN) in a managed care setting. 
METHODS: Data were obtained from the 30 million member HealthCore Integrated 
Research Databaseä. Patients with at least 1 claim for diabetes, antidiabetic agents 
and DPN and q2 claims for MPM between July 1, 2004 and April 30, 2007, with q6 
months pre and q12 months post index eligibility were matched 2:1 on age, gender 
and health plan region with non-MPM treated patients. Cost comparisons were per-
formed on the population 65 years old to assure full capture of health care costs. 
RESULTS: A total of 89 MPM treated patients and 178 matched controls were identi-
ﬁed, 65% were male and mean (SD) age was 60.1 (o9.3) years. MPM treated patients 
were more likely to be treated with anticonvulsants in the pre-index period (p  0.01). 
There was a 31% reduction in the use of anticonvulsants post-index for the MPM 
group and a 10% reduction in the control group. There was a meaningful albeit non-
signiﬁcant cost difference in the 12 month post-index DPN related costs between the 
65 year old MPM and control groups ($1029 n  56 vs. $1401 n  112). CONCLU-
SIONS: This observational cohort study demonstrated a reduction in the use of anti-
convulsant medication among the MPM cohort, perhaps denoting a reduction in the 
need for pain medication, and costs related to DPN were lower in the MPM group. 
Additional randomized controlled trials need to be conducted to validate these 
results.
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THE CLINICAL EFFECTIVENESS OF SOMATROPIN (GENOTROPIN®) IN 
CHILDREN WITH SHORT STATURE: A SYSTEMATIC REVIEW
Heatley RM1, Walsh C2, Loftus J3
1Evidence Research Unit, Macclesﬁeld, UK, 2Complete Medical Group, Macclesﬁeld, UK, 
3Pﬁzer Ltd, Walton on the Hill, UK
OBJECTIVES: Genotropin® is a brand of somatropin (human growth hormone [GH]) 
licensed for the treatment of children with short stature due to: growth hormone 
deﬁciency (GHD), Prader-Willi syndrome (PWS), Turner syndrome (TS), chronic renal 
insufﬁciency (CRI) and those born small for gestational age (SGA). Although ﬁnal 
height (FH) is probably the most effective outcome for measuring somatropin effective-
ness, there is a lack of randomised controlled trial (RCT) data reporting FH and other 
important outcomes, such as quality of life (QoL) which is rarely reported for children. 
The objective of this systematic review (SR) of RCTs and observational studies was 
to investigate the efﬁcacy and safety of Genotropin in children with these indications, 
and identify whether the lack of relevant RCT data in this therapy area can be sup-
plemented with observational studies. METHODS: Predeﬁned search terms were used 
to search eight electronic databases, including Medline and Embase, for published 
English language studies. Additionally, bibliographies of included articles were exam-
ined for relevant studies. RCTs or observational studies were retrieved if they included 
a population of children (16 years) with GHD, PWS, TS, CRI or SGA treated with 
Genotropin. The main reported outcome measures included FH and short-term 
growth responses, e.g. growth velocity. RESULTS: Thirty RCTs and 37 observational 
studies were identiﬁed. No RCTs were identiﬁed that included data on QoL. One RCT 
and 11 observational studies reported data for FH. FH was consistently improved 
following treatment with Genotropin. Seven of the observational studies were based 
on data sourced from the Pﬁzer International Growth Survey (KIGS), which showed 
signiﬁcant gains of up to 2.3 height standard deviation scores. CONCLUSIONS: This 
SR reveals the paucity of long-term RCTs reporting data on FH and QoL in children, 
thus highlighting the consequent importance of observational studies of GH therapy, 
such as KIGS, which reports FH.
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ANTIDIABETIC DRUG UTILIZATION IN A UNIVERSITY HEALTH CARE 
SETTING
Mousnad M1, Ibrahim MIM2
1Universiti Sains Malaysia, Penang , Malaysia, 2Universiti Sains Malaysia, Penang, Malaysia
OBJECTIVES: Diabetes mellitus (DM) is a worldwide problem. Data regarding the 
utilization pattern of antidiabetics is lacking in Malaysia. The present study evaluated 
the prescribing trends of antidiabetic drugs in a university health care centre in Malay-
sia during the years 2002 and 2003. METHODS: Retrospective data for 2002 and 
2003 was collected from the USM Center for Knowledge, Communication and Tech-
nology. A drug utilization study using the Anatomical Therapeutic Chemical classiﬁca-
tion and deﬁned daily doses (ATC/DDD) methods was conducted. Selected drug use 
indicators as suggested by WHO/INRUD were used in this study. Prescribing preva-
lence was expressed by the DDD methodology. The utilization of antidiabetic drugs 
was expressed as the number of deﬁned daily doses per 1000 inhabitants per day 
(DDD/1000/day). RESULTS: The number of antidiabetic patients was 300. Total 
1289 and 1565 prescription data were collated from the database for the years 2002 
and 2003, respectively. The total number of different drugs prescribed in 2002 and 
2003 were 2982 and 3345, respectively. Among these, 1997 (67.0%) of drugs pre-
scribed in 2002 and 2389 (71.4%) of drugs prescribed in 2003 were antidiabetics. In 
general, the consumption of antidiabetics in USM Heath Centre increased from 3.4 
DDD/1000/day in 2002 to 4.7 DDD/1000/day in 2003. Signiﬁcant antidiabetic pre-
scribing patterns related to metformin and gliclazide were observed in this study. 
Metformin was the most commonly prescribed drug while gliclazide was the most 
consumed drug. CONCLUSIONS: It is reasonable to conclude that diabetic medicine 
utilization is on increase. Much attention and effort should be directed towards 
establishing the burden of diabetes in USM in economic terms.
PDB9
IMPACT OF FDA SAFETY WARNINGS ON SUBSEQUENT DIABETES 
CARE FOR USERS OF ROSIGLITAZONE
Huse D, Bizier R
Thomson Reuters, Cambridge, MA, USA
OBJECTIVES: To understand the impact of the May 2007 safety warning about 
rosiglitazone from the US Food and Drug Administration (FDA) on the subsequent 
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diabetes treatment for users of this drug. METHODS: Patients were selected from the 
MarketScan® databases who ﬁlled at least one prescription for rosiglitazone during 
the second quarter of 2007 and received at least 90 days of therapy during the ﬁrst 
half of 2007. Each patient’s use of all antidiabetic drugs was tracked by calendar 
quarter during 2007 and 2008. For comparison, similar longitudinal proﬁles were 
constructed for users of pioglitazone (same drug class) and for metformin (different 
class of oral antidiabetic agent). The net impact of the FDA safety warnings on user 
of rosiglitazone was assessed by comparing changes in their antidiabetic drug con-
sumption with those for users of pioglitazone and and metformin. RESULTS: The 
study cohorts included: 37,087 rosiglitazone, 43,607 pioglitazone, and 147,055 met-
formin users. The groups were demographically similar, except for a higher proportion 
of women in the metformin cohort. By the end of 2008 only 32.6% of the rosiglitazone 
cohort continued to ﬁll prescriptions for that agent, compared to 66.5% for piogli-
tazone and 76.5% for metformin. 18.9% of rosiglitazone users switched to piogli-
tazone. They also were more likely than the other cohorts to start using a DPP4 
inhibitor (8.6% v. 6.1% and 5.2%, respectively) or insulin (5.3% v. 4.2% and 4.1%). 
CONCLUSIONS: The safety warnings in 2007 led to a high rate of discontinuation 
of rosiglitazone use, some of which was replaced by pioglitazone and other drugs with 
different mechanisms of action. However, new prescriptions did not fully offset the 
discontinuation of rosiglitazone, so the net result was a reduction in the average 
intensity of therapy.
PDB10
DIFFERENT PERSISTENCE WITH A BASAL SUPPORTED ORAL THERAPY 
(BOT) LEADS TO UNEQUAL DISTRIBUTIONS OF INSULIN TREATMENT 
REGIMENS IN TYPE-2-DIABETICS
Reichelt A1, Pfohl M2, Dippel FW3, Pirk O1, Kotowa W1
1IMS HEALTH GmbH & Co. OHG HEOR, Nuremberg, Germany, 2Evangelisches Bethesda-
Johanniter-Klinikum GmbH, Duisburg, Germany, 3Sanoﬁ-Aventis Deutschland GmbH, Berlin, 
Germany
OBJECTIVES: Results from a representative German database [1] and ﬁndings from 
a real-life cross-sectional study [2] show an unequal distribution between basal sup-
ported oral therapy (BOT) and intensiﬁed conventional therapy (ICT) regimens in 
type-2-diabetics (T2D) treated with either insulin glargine (GLA) or NPH-insulin 
(NPH). This study assesses whether different persistence on the respective BOT can 
be the reason. METHODS: A Markov model was developed simulating the transition 
from BOT to ICT in the course of ten years in T2D treated either with GLA or NPH. 
Persistence data were obtained from the IMS Disease Analyzer database [3]. The model 
cohort consisted of 44,366 [4,5] statutorily-insured T2D starting a BOT either with 
GLA or NPH at a ratio of 1:1. RESULTS: The number of patients switching from 
BOT to ICT was continually lower in the GLA vs. NPH group (p  0.0002). Therefore, 
the ratio of BOT to ICT in the GLA and NPH group changed differently over time. 
After two years 11,840 patients (from 22,183) remained on BOT in the GLA group 
compared to 6,928 patients (from 22,183) in the NPH group. After 6.50 years all 
patients who have started with a NPH-based BOT switched to ICT. Complete transi-
tion to ICT took 1,75 years longer in the GLA group (8.25 years). The model simula-
tion yield BOT : ICT ratios in the ﬁrst quarter of year 3 for GLA (46%:54%) and for 
NPH (24%:76%), similar to the above mentioned ﬁndings [1;2]. CONCLUSIONS: 
The simulation indicates a correlation between persistence on a basal supported oral 
therapy and the resulting distribution of treatment regimens (BOT : ICT ratio) in T2D 
either treated with GLA or NPH in real-life cross-sectional studies. References: [1] 
ABDA claims data for ambulatory prescriptions, [2] J Med Econ 2008; 11:695–712, 
[3] Diabetologie und Stoffwechsel 2009; 4:1–6 [4] DDU: Gesundheitsbericht Diabetes 
2008 [5] Diabetes und Stoffwechsel 2003; 12:83–94.
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DATABASE ANALYSIS ON PREVALENCE AND RISK FACTORS OF 
DIABETIC FOOT SYNDROME (DFS) IN GERMANY
Lauterbach S1, Kostev K2, Kohlmann T3, Schröder-Bernhardi D2
1Rotes Kreuz Hospital, Kassel, Germany, 2IMS HEALTH GmbH & Co. OHG, Frankfurt am 
Main, Germany, 3University of Greifswald, Greifswald, Germany
OBJECTIVES: To show the prevalence of DFS and its risk factors in Germany in 
2008. METHODS: Analyses used IMS® Disease Analyzer database (includes repre-
sentative information on approximately 12 million patients from more than 3000 
ofﬁce-based physicians). Patients with a diagnosis of diabetes mellitus in 2008 were 
included. All documented diagnoses of these patients in 2008 based on ICD-10 (inter-
national classiﬁcation of diseases) were analyzed. RESULTS: Data from 116,207 dia- 
betes type-2 patients (T2D) and 9820 (7.8%) diabetes type 1 patients (T1D) were 
analyzed. DFS was registered among 2.6% [2.3–2.9] of T1D patients and 2.1% 
[2.0–2.2] of T2D patients. Projected to national level there are approximately 130,000 
patients diagnosed in 2008. But much more patients had high risk of DFS: 12.0% 
of T1D and 10.5% of T2D patients are discovered among diabetic neuropathy, 
10.9%/12.3% diabetic angiopathy. Additionally 3.6% (T1D) / 9.4% (T2D) were 
diagnosed with foot mycoses and 3.6% (T1D) / 7.0% (T2D) with an open wound 
of foot. The total number of T2D patients with DFS was 2463, mean age 70.9 
[SD: 11.0] years, 1045 (42.4%) women. A total of 553 (22.5%) patients had diabetes 
for 1 year, 1195 (48.5%) for 2–5 years, 547 (22.2%) for 6–10 and 168 (6.8%) 
for more than 10 years. CONCLUSIONS: Results from this analysis of a large repre-
sentative German database show, that even though the prevalence of DFS among 
diabetic patients is relatively low, the prevalence of the main risk factors for DFS 
is much higher. Preventive efforts for avoiding DFS should mainly target these risk 
factors.
PDB12
GLYCATED HAEMOGLOBIN AS A SURROGATE MARKER FOR THE 
APPEARANCE AND PROGRESSION OF RETINOPATHY IN TYPE-1 
DIABETES MELLITUS: SYSTEMATIC REVIEW AND META-ANALYSIS
Wieczorek A1, Marcisz A1, Rys P1, Skrzekowska-Baran I2, Plisko R1, Wladysiuk M3
1HTA Consulting, Krakow, Poland, 2Novo Nordisk, Inc., Warsaw, Mazowieckie, Poland, 
3HTA Consulting, Krakow, Malopolska, Poland
OBJECTIVES: We performed a systematic review and meta-analysis to examine the 
association between HbA1c and the appearance and progression of diabetic retinopathy 
(DR) in T1DM. METHODS: The two electronic medical databases (MEDLINE, 
CENTRAL) were searched to identify all papers reporting HbA1c level and retinopa-
thy in T1DM. Observational and randomized, controlled trials (RCTs) with at least 
one year of follow-up were included. Estimates were made of the adjusted relative risk 
(RR) of complications for an increase in HbA1c of 1%. If available data were insufﬁ-
cient to calculate RR, the odds ratio (OR) was estimated. Weighted mean differences 
(WMD) in HbA1c level between the case group (i.e. with DR) and the control group 
(i.e. without DR) were also calculated. RESULTS: We identiﬁed 16 trials (4176 
patients) that fulﬁlled the inclusion criteria. Based on four RCTs (n  1597), pooled 
RR for progression of DR was calculated as 1.24 (95%CI:1.01–1.52) for an increase 
in HbA1c of 1%. Pooled data from four observational studies (n  910) showed that 
RR of the incidence of DR was 1.59 (CI:1.34–1.89) for HbA1c increase of 1%. A 
meta-analysis of eight observational studies (n  1171) demonstrated a lower HbA1c 
level in patients without DR compared with patients with DR (WMD  0.82 [CI:0.69–
0.96]). In addition, a meta-analysis of ﬁve observational studies revealed that mean 
HbA1c values were signiﬁcantly lower in the group without progression of DR relative 
to the group with DR (WMD  1.05 [CI:0.37–1.72]). One RCT included data on 
visual deterioration and macular oedema; analysis demonstrated that an increase in 
HbA1c level of 1% increased the risk of both macular oedema (RR  1.81 [CI:1.17–
2.81]) and visual deterioration (OR  2.2 [CI:1.2–3.9]). CONCLUSIONS: The results 
of our systematic review indicate a strong correlation between HbA1c level and appear-
ance and progression of DR in T1DM. Thus, HbA1c may be considered an excellent 
surrogate endpoint for DR in T1DM.
PDB13
MEDICATION PATTERN AND RISK OF STROKE AMONG TYPE II 
DIABETES MELLITUS IN TAIWAN-A POPULATION-BASED STUDY
Wu CS1, Tang CH2, Huang HM3
1Taipei City Hospital, Zhong Xing Branch, Taipei, Taiwan, 2Taipei Medical University, Taipei, 
Taiwan, 3Taipei City Hospital, Woman and Children Branch, Taipei, Taiwan
OBJECTIVES: This study uses 5-year population Type II diabetes mellitus data to 
determine the risk of stroke in Taiwan, taking into consideration the age and gender 
of patients, as well as medication pattern. METHODS: The 2,123,104 diabetic 
patients data used are from the Taiwan National Health Insurance Research Database 
covering the period from 1999 to 2004. Newly-diagnosed diabetic patient was deﬁned 
as had 3 or more visits or at least a diabetic code during admission or emergency visit 
in 1999 with a diagnosis of (ICD-9-CM code 250) and who did not have any diabetic 
code in 1998, a total of 681,188 were identiﬁed from the database. 45,949 sample 
patients were identiﬁed from the database by a principal diagnosis of stoke (ICD-9-
CM code 430–438) during next 5 years. The analyses were descriptive in nature, 
including numbers and percentages for the categorical variables. Multiple logistic 
regression was used to compute the relative risk for the associations between different 
medication rate, health service type, physicians, diabetic patients and clinical compli-
cations. RESULTS: We ﬁnd that for the period under examination, there was statistic 
signiﬁcant increase in diabetic stroke incidence with male, age, medication rate, hos-
pital level visit rate, same physician visit rate and bed sore, neuropathy complications. 
CONCLUSIONS: Our ﬁnding of signiﬁcant risk of stroke in diabetic patients of dif-
ferent medication pattern may be explained by severity of disease and important of 
management of diabetic patients.
DIABETES/ENDOCRINE DISORDERS – Cost Studies
PDB14
THE BUDGET IMPACT ANALYSIS OF VILDAGLIPTIN IN TYPE 2 
DIABETES IN POLAND
Walczak J, Nogas G, Gebus E, Pawlik D, Pacocha K
Arcana Institute, Cracow, Poland
OBJECTIVES: To estimate the impact of the of vildagliptin reimbursement within the 
limits of type 2 diabetes mellitus treatment on the budget of the National Health Fund 
in Poland. METHODS: The budget impact analysis was performed with two years 
time horizon, from the public payer’s perspective (National Health Fund) and also 
from both payers’ perspective (National Health Fund and the patient). Polish cost data 
was used (only oral anti-hyperglycemic drugs were considered). Two scenarios were 
compared: present—without reimbursement of vildagliptin, and future—after reim-
bursement of vildagliptin. The prognosis of market vildagliptin shares, sent by the 
Novartis Poland, was used in the analysis. The rate of other oral anti-hyperglycemic 
drugs was estimated on the base of IMS data about the number of units sold in the 
ﬁrst three quarters of the year 2008. Sensitivity analysis was performed to test the 
impact of changes in the assumed parameters of the analysis. RESULTS: Assuming 
the reimbursement of vildagliptin annual expenses from the budget of National Health 
Fund for anti-hyperglycemic drugs would raise by 320.4 thousand PLN (72 thousand 
a) in 2009 and 612.3 thousand PLN (137.7 thousand a) in 2010. Annual expenses 
